Pfizer’s Tukysa Shows Promising Maintenance Therapy Results in HER2+ Metastatic Breast Cancer

Pfizer’s oral tyrosine kinase inhibitor (TKI), Tukysa (tucatinib), has demonstrated improvements in progression-free survival (PFS) in the maintenance setting for HER2-positive metastatic breast cancer during the Phase III HER2CLIMB-05 trial (NCT05132582). Evaluated alongside first-line trastuzumab and pertuzumab, Tukysa met its primary endpoint, showing statistically significant PFS benefits compared with placebo.

The trial also confirmed the tolerability and safety of Tukysa when combined with standard of care (SoC) therapies, with safety profiles consistent with each individual treatment. These results were observed in patients following chemotherapy induction, highlighting the potential of Tukysa to enhance outcomes in the post-chemotherapy maintenance setting.

Pfizer plans to present detailed HER2CLIMB-05 results at a forthcoming medical conference and submit them to regulatory authorities. Analysts at GlobalData project that Tukysa could become a blockbuster drug by 2028, signaling a potential shift toward less chemotherapy-intensive maintenance strategies in metastatic breast cancer.

19-10-2025